Post Market Clinical Follow-up of LARS® Ligaments Associated to Fixations in Acute or Chronic Injury of the Anterior Cruciate Ligament (ACL), Posterior Cruciate (PCL) or Medial Collateral (MCL) Ligaments of the Knee

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMOVMEDIX

About this trial

This study aims to assess the long-term safety, stability, knee function, pain, and satisfaction of patients who received a LARS® ligament to treat an injury of one of the main ligaments of the knee.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient who received study information and provided informed consent to participate in the study, where required by applicable local regulations and ethics committee requirements.

Patient who underwent ligamentoplasty using one or more LARS® artificial ligaments for posterior cruciate ligament (PCL), anterior cruciate ligament (ACL), and/or medial collateral ligament (MCL) in only 1 leg (knee) reconstruction between 2015 and 2018 (or since 9 to 12 years from data collection time-point).

Surgical procedure performed using LARS® ligaments in accordance with the intended use and routine clinical practice.

Availability of adequate medical records and follow-up documentation allowing assessment of the study endpoints related to safety and performance

Disqualifiers

Patients aged less than 18 years at the time of the ligamentoplasty procedure.

Patients presenting, at the date of surgery, with any contraindication to ligamentoplasty procedures and/or contraindications specified in the applicable Instructions for Use (IFU) of the implanted device.

Patients who are lost to follow-up, deceased at the time of study conduct.

Patients who have undergone bilateral ligamentoplasty.

Trial population

Male or female patient who underwent ligamentoplasty in 1 Knee (1leg) using one or more LARS® artificial ligaments, with or without associated fixation devices between 2015 and 2018.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

257 Participants
are grouped into 5 trial groups
Group A: MCL32
Group B: ACL AC30DB/AC60DB
Group C: ACL ACTOR8/ACTOR10
Group D: PCL PC60/PC80
Group E: PCL ACTOR8/ACTOR10

Trial outcomes

Primary outcomes

1

Device failure proportion

The primary safety endpoint is the proportion of knees with a device failure at 10 years post-procedure. Device failure is defined as implant removal for any aseptic reason, including implant rupture.

Time frame
10 years

Secondary outcomes

1

Occurence of knee-related adverse events

Perioperative and postoperative related to ligaments or fixations or instruments up to 10 years postoperatively. Occurence by % on the total number of ligaments assessed.

Time frame
10 years
2

Occurence of device deficiency

Description of device deficiencies occurring within 10 years post-procedure, related to the ligament reconstruction and/or fixation devices. Occurence by % on the total number of ligaments assessed.

Time frame
10 years
3

Occurence of reintervention

Description of reintervention occurring within 10 years post-procedure, related to any cause, without device removal. Occurence by % on the total number of ligaments assessed.

Time frame
10 years
4

Pain level

Pain level at 10 years measured by Knee injury and Osteoarthritis Outcome Score (KOOS) with pain subscore. It is composed on 9 questions. Each item is evaluated on 4 points ranking from 0 (none pain) to 4 (extreme pain)

Time frame
10 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

MOVMEDIX

Lead sponsor

nexialist

Collaborator

1Med

Collaborator

This trial is not recruiting at the moment. You can still explore other options: